SXTP

Announcements

Nothing here yet

Daily updates

• 60 Degrees Pharmaceuticals will disclose the interim analysis outcome from its tafenoquine study in hospitalized patients with severe babesiosis on October 6, 2026.Oct 5, 2026

FDA designations

Nothing here yet

News

• 60 Degrees Pharmaceuticals plans January 2027 hospitalized babesiosis data readout and will seek a pre-sNDA meeting with the FDAOct 6, 2026
• Sixty Degrees Pharmaceuticals announces the date for releasing interim data from its hospitalized babesiosis studyOct 1, 2026
• 60 Degrees Pharmaceuticals signed an exclusive option agreement with Florida State University to advance castanospermine for tick-borne diseasesJul 8, 2026
• 60 Degrees Pharmaceuticals begins early enrollment of first seasonal patient in tafenoquine babesiosis trialMay 26, 2026
• 60 Degrees Pharmaceuticals reported all patients were cured of babesiosis after tafenoquine treatment in an expanded-use clinical trialMar 11, 2026